Home > Insider Trading > Filing (0001209191-23-031918)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1426800	Assembly Biosciences Inc.	ASMB	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1945064	M Jeanette Bjorkquist	C/O Assembly Biosciences, Inc. 331 Oyster Point Blvd, Fourth Floor South San Francisco CA 94080	Principal Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-22	1,500	$0.00	27,806	No	4	A	Direct
Common Stock	Disposition	2023-05-23	274	$1.04	27,532	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

Represents shares of common stock issuable under a performance-based restricted stock unit award dated July 22, 2021. On May 22, 2023, the performance-based vesting conditions were achieved. These shares of common stock vest in two equal installments, assuming continuous service on each vesting date, as follows: May 22, 2023 and May 22, 2024.
Includes 2,500 shares acquired under the Assembly Biosciences, Inc. Amended and Restated 2018 Employee Stock Purchase Plan on May 12, 2023.
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.07, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.